Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications.
Intraperitoneal radioactive chromic phosphate was administered to 69 patients with Stage I and II ovarian carcinoma who had undergone comprehensive surgical staging. Intestinal obstruction requiring surgical intervention occurred in four patients and was the most severe complication. Abdominal pain was the most common post-therapy complaint. Attention to time and technique of drug administration could minimize complications.
Walton
L A
LA
Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill 27599-7570.
Yadusky
A
A
Rubinstein
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D002857:Chromium / Q000008:administration & dosage; D017608:Chromium Compounds; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007274:Injections, Intraperitoneal; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000532:radiotherapy*; D010710:Phosphates / Q000008:administration & dosage; D010761:Phosphorus Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects*
D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D002857:Chromium; C509369:chromic phosphate; D008558:Melphalan